• AwardCall for Excellence Award Nominations

    The awards are: Emerging Chapter Award, Established Chapter Excellence Award, Special Interest Group Excellence Award, Excellence in Clinical Practice Award, Excellence in Community Service Award, Excellence in Education Award, Excellence in Leadership Award, and Excellence in Research Award.

    The nominations are tallied in July and the winners are announced every year during the Awards Celebration at the GAPNA Annual Conference.

    Now is the time to nominate a colleague or yourself - DEADLINE is June 1, 2019.

    Get started... nominate today!

  • Poster Presentation

       

    This 22-module curriculum provides a basic knowledge base for Nurse Practitioners who looking to advance their expertise in caring for patients with dementia.
     

    FREE to GAPNA members until September 1, 2019

  • GAPNA Exchange

       

    GAPNA Exchange is a private, secure community for members to share ideas, ask questions, lend expertise, and network with peers.

    It features both an Open Forum discussion area along with smaller, segmented communities.

    Interact with GAPNA members wherever and whenever!

    Go to GAPNA Exchange

  • GAPNA Foundation Awards and Grants

       

    GAPNA Foundation has $11,000 to give away in grants!

    The primary goal of the GAPNA Foundation is to provide financial support for research and educational opportunities.

    Find out if you qualify and submit your application by May 15, 2019!

    Visit GAPNA Foundation Awards and Grants

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer a series of CNE programs available to GAPNA members. "Alzheimer’s Disease Today and Tomorrow: Optimal Treatment and Collaborative Care," is the first program offered.

    What are the state-of-the-art strategies for managing the symptoms of Alzheimer’s disease? How can the multidisciplinary team work together to ensure timely intervention and optimal outcomes?

    Find out about it!

  • Meet the Candidates for the 2019-2020 BOD!
    The time to vote is coming soon!

    Please take a moment to read about this year’s candidates and why they feel they should be chosen for the position noted.

    MEET THE CANDIDATES IN ADVANCE OF YOUR VOTE   >

2014 - Summer - Volume 33, Number 2

Methotrexate Recommended as First-Line Therapy for Early, Poor-Prognosis Rheumatoid Arthritis

Most evidence-based guidelines call for methotrexate (MTX) by itself as first-line therapy for rheumatoid arthritis (RA).

Recent trials, however, suggest that combination therapy may be better. Yet, a new study concludes MTX should be first-line therapy for patients with early rheumatoid arthritis even if they have poor prognostic features.

The researchers compared the results of initial MTX monotherapy with the option to step up to combination therapy with immediate initial combination therapy in patients with RA and an early poor prognosis.

Subscribe to 2014 - Summer - Volume 33, Number 2